home / stock / xair / xair news

XAIR News and Press, Beyond Air Inc. From 10/20/23

Stock Information
Company Name: Beyond Air Inc.
Stock Symbol: XAIR
Market: NYSE
Website: beyondair.net
Menu
XAIR XAIR Quote XAIR Short XAIR News XAIR Articles XAIR Message Board
Get XAIR Alerts

News, Short Squeeze, Breakout and More Instantly...
XAIR - Beyond Air Inc. (NASDAQ: XAIR) Near the Top of Equities by Percentage Gain on 10/20

Beyond Air, Inc. (NASDAQ: XAIR) is one of today's top gainers. The company's shares are currently up 9.28% on the day to $2.42. Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing ...
XAIR - Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve...

XAIR - Beyond Air® To Participate in the Truist Securities BioPharma Symposium

GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve...

XAIR - Beyond Cancer(TM) Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance First-in-human Phase 1 clinical study is ongoing with initial data expected to be released on November 3 rd at the Society for Immunother...
XAIR - Beyond Cancer(TM) Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone Pooled analysis of combination studies of 50,000 or 100,000 ppm UNO with anti-mPD-1 demonstrated more than a doubling in surviv...

XAIR - Beyond Air receives Innovative Technology contract from Vizient

2023-10-16 07:19:48 ET More on Beyond Air Beyond Air enters into strategic collaboration with Getz Healthcare Beyond Air spikes after insider purchase Seeking Alpha’s Quant Rating on Beyond Air For further details see: Beyond Air receives Innovativ...

XAIR - Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH

GARDEN CITY, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improv...
XAIR - Beyond Cancer(TM) Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will pr...

XAIR - Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference

GARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve...

XAIR - Beyond Cancer(TM) to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd. (the “Company”), an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced t...
Previous 10 Next 10